-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.

What is NETosis?
In the first video of our NETs educational series, Dr Andrew Retter, Volition’s Chief Medical Officer, discusses the process of NETosis, its role in sepsis and the development of Volition’s H3.1 assay.
NETosis is the release of neutrophil extracellular traps (NETs), where neutrophils eject DNA to trap pathogens. Traditionally, neutrophils were only known for phagocytosis, but research has shown that they can also degranulate and release NETs, which can capture bacteria, viruses and fungi.
Explaining how Nu.Q® H3.1 acts as a marker for NETosis, aiding in the diagnosis, monitoring and potential treatment of sepsis, this video dives into the biological mechanisms of NET release, showing how NETs can create both positive and harmful responses.

Click here for the next video in our series: Clinical Evidence and Upcoming Studies
Related Articles
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields